| Q33607563 | Animal models of C-reactive protein |
| Q54946647 | C-Reactive Protein in Atherothrombosis and Angiogenesis. |
| Q46708458 | C-reactive protein and C1q regulate platelet adhesion and activation on adsorbed immunoglobulin G and albumin |
| Q36622467 | C-reactive protein and diabetic retinopathy in Chinese patients with type 2 diabetes mellitus |
| Q37754545 | C-reactive protein at the interface between innate immunity and inflammation |
| Q35997686 | C-reactive protein in end-stage renal disease: are there reasons to measure it? |
| Q27013635 | C-reactive protein in human atherogenesis: facts and fiction |
| Q24321501 | C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells |
| Q36097479 | CRP after 2004. |
| Q37624992 | Chapter 7: Cell protective functions of secretory Clusterin (sCLU). |
| Q51770229 | Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d deposition and neointimal fibrosis. |
| Q35133725 | Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium |
| Q37288362 | Complement activation: an emerging player in the pathogenesis of cardiovascular disease |
| Q37820714 | Complement in atherosclerosis: friend or foe? |
| Q37362130 | Decay-accelerating factor suppresses complement C3 activation and retards atherosclerosis in low-density lipoprotein receptor-deficient mice |
| Q36836028 | Enzymatically Modified Low-Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease |
| Q41854751 | Enzymatically modified low-density lipoprotein is recognized by c1q and activates the classical complement pathway |
| Q46450566 | Fatty acids liberated from low-density lipoprotein trigger endothelial apoptosis via mitogen-activated protein kinases |
| Q39016069 | Functional Transformation of C-reactive Protein by Hydrogen Peroxide |
| Q55313873 | High-Mobility Group Box 1-Induced Complement Activation Causes Sterile Inflammation. |
| Q35963030 | Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia |
| Q31132267 | Impact of glutathione peroxidase-1 deficiency on macrophage foam cell formation and proliferation: implications for atherogenesis |
| Q37285802 | Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications |
| Q37283121 | Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation |
| Q47873792 | Malarial anemia: digestive vacuole of Plasmodium falciparum mediates complement deposition on bystander cells to provoke hemophagocytosis |
| Q36012953 | Metabolic syndrome: the danger signal in atherosclerosis |
| Q43292217 | Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. |
| Q52938773 | More reactive and less reactive C-reactive protein. |
| Q43702621 | Myeloperoxidase influences the complement regulatory function of modified C-reactive protein |
| Q36008865 | Pattern recognition by pentraxins |
| Q37328097 | Pentraxins, anti-pentraxin antibodies, and atherosclerosis |
| Q34446461 | Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself |
| Q35309510 | Protective molecules and their cognate antibodies: new players in autoimmunity |
| Q37731432 | Should we measure C-reactive protein on earth or just on JUPITER? |
| Q37281358 | Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist |
| Q35896873 | Structural and functional anatomy of the globular domain of complement protein C1q. |
| Q35999439 | The connection between C-reactive protein and atherosclerosis |
| Q36423484 | The pro-atherogenic effects of macrophages are reduced upon formation of a complex between C-reactive protein and lysophosphatidylcholine |
| Q38532361 | The role of complement activation in atherogenesis: the first 40 years |
| Q30475959 | Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. |
| Q42841077 | Unsaturated fatty acids drive disintegrin and metalloproteinase (ADAM)-dependent cell adhesion, proliferation, and migration by modulating membrane fluidity |